XML 28 R15.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Goodwill and Intangible Assets, Net | 3 Months Ended
--- | ---
Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets, Net | Goodwill and Intangible Assets, Net Changes in the carrying amount of goodwill were as follows:
(In millions) | U.S. Pharmaceutical and Specialty Solutions |  | European Pharmaceutical Solutions |  | Medical-Surgical Solutions |  | Other |  | Total
Balance, March 31, 2018 | $ | 4,110 |  |  | $ | 1,850 |  |  | $ | 2,070 |  |  | $ | 2,894 |  |  | $ | 10,924 |
Goodwill acquired | — |  |  | 31 |  |  | 360 |  |  | — |  |  | 391 |
Goodwill impairment charges | — |  |  | (570 | ) |  | — |  |  | — |  |  | (570 | )
Acquisition accounting, transfers and other adjustments | 4 |  |  | — |  |  | — |  |  | 6 |  |  | 10 |
Foreign currency translation adjustments, net | (36 | ) |  | (98 | ) |  | — |  |  | (36 | ) |  | (170 | )
Balance, June 30, 2018 | $ | 4,078 |  |  | $ | 1,213 |  |  | $ | 2,430 |  |  | $ | 2,864 |  |  | $ | 10,585 |
As of June 30, 2018, accumulated goodwill impairment losses were $1,793 million and $448 million in our European Pharmaceutical Solutions segment and Other. As of March 31, 2018, accumulated goodwill impairment losses were $1,299 million and $456 million in our European Pharmaceutical segment and Other. Refer to Financial Note 3, “Goodwill Impairment Charges,” for more information on goodwill impairment charges recorded in the first quarter of 2019. Information regarding intangible assets is as follows:
| June 30, 2018 |  | March 31, 2018
(Dollars in millions) | Weighted Average Remaining Amortization Period (years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount
Customer relationships | 13 |  | $ | 4,038 |  |  | $ | (1,724 | ) |  | $ | 2,314 |  |  | $ | 3,619 |  |  | $ | (1,550 | ) |  | $ | 2,069 |
Service agreements | 12 |  | 1,020 |  |  | (392 | ) |  | 628 |  |  | 1,037 |  |  | (386 | ) |  | 651 |
Pharmacy licenses | 25 |  | 766 |  |  | (336 | ) |  | 430 |  |  | 684 |  |  | (196 | ) |  | 488 |
Trademarks and trade names | 14 |  | 938 |  |  | (207 | ) |  | 731 |  |  | 932 |  |  | (187 | ) |  | 745 |
Technology | 4 |  | 146 |  |  | (87 | ) |  | 59 |  |  | 147 |  |  | (84 | ) |  | 63 |
Other | 5 |  | 285 |  |  | (189 | ) |  | 96 |  |  | 262 |  |  | (176 | ) |  | 86 |
Total |  |  | $ | 7,193 |  |  | $ | (2,935 | ) |  | $ | 4,258 |  |  | $ | 6,681 |  |  | $ | (2,579 | ) |  | $ | 4,102 |
Amortization expense of intangible assets was $122 million and $121 million for the quarters ended June 30, 2018 and 2017. Estimated annual amortization expense of these assets is as follows: $344 million, $441 million, $423 million, $391 million and $282 million for the remainder of 2019 and each of the succeeding years through 2023 and $2,377 million thereafter. All intangible assets were subject to amortization as of June 30, 2018 and March 31, 2018.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration